Not Signed In -
Glaucoma |
|
|
Clinical Trial: A long-term safety study of once-daily Travatan
This study is currently recruiting patients.
|
Purpose
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Glaucoma, Open-Angle Ocular Hypertension | Drug: Travoprost (0.004%) | Phase IV |
MedlinePlus related topics: Eye Diseases; Glaucoma
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Location and Contact Information
Alcon Clinical +1-817-568-6747 IntlDev@alconlabs.com
Europe, ; Recruiting
More Information
Study ID Numbers: C-02-20
Record last reviewed: January 2003
Last Updated: January 6, 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051168
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: January 2003
Last Updated: January 6, 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051168
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
